[Use of Aloglutamol in uremic patients on dialysis (author's transl].
The authors experimented Aloglutamol (an organic salt of aluminium) in uremic patients on dialysis to detect its phosphate-binding properties and study its use in the treatment of uremic osteodystropy. They report good results: predialysis Ca increased; serum PO4 and alcaline phosphatase levels decreased; Ca X PO4 was normalized; itch, muscular weakness and constipation decreased; no side-effects appeared, and the drug has a good taste. Therefore it is considered to be most useful in the treatment of hyperphosphatemia in uremia.
D000328:Adult; D000535:Aluminum / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000097:blood / Q000188:drug therapy; D005260:Female; D005942:Gluconates; D006801:Humans; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis; D014325:Tromethamine / Q000031:analogs & derivatives; D014511:Uremia / Q000097:blood / Q000188:drug therapy*
D005942:Gluconates; D010710:Phosphates; D014325:Tromethamine; D000535:Aluminum; D002118:Calcium
Observations cliniques sur l'emploi d'un nouveau sel organique d'aluminium dans l'urémie en cours de traitement dialytique.